| Literature DB >> 25851441 |
Xuefei Cao, Haixia Lin, Levan Muskhelishvili, John Latendresse, Patricia Richter, Robert H Heflich.
Abstract
BACKGROUND: The cadmium (Cd) present in air pollutants and cigarette smoke has the potential of causing multiple adverse health outcomes involving damage to pulmonary and cardiovascular tissue. Injury to pulmonary epithelium may include alterations in tight junction (TJ) integrity, resulting in impaired epithelial barrier function and enhanced penetration of chemicals and biomolecules. Herein, we investigated mechanisms involved in the disruption of TJ integrity by Cd exposure using an in vitro human air-liquid-interface (ALI) airway tissue model derived from normal primary human bronchial epithelial cells.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25851441 PMCID: PMC4352288 DOI: 10.1186/s12931-015-0191-9
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Figure 1Morphological characterization of ALI human airway cultures. ALI cultures were fixed in 10% formalin 5 weeks after the initial seeding onto the permeable membrane support. Tissue sections were stained with H&E (A), p63 (B), Ki67 (C), and PAS (D). Examples of positively stained cells are indicated by arrows. The arrows in (A), (B), (C), and (D) indicate ciliated cells, basal cells, actively proliferating cells, and goblet cells, respectively.
Figure 2Evaluation of transepithelial electrical resistance (TEER) and cellular toxicity in CdCl -treated human ALI cultures. Cultures were treated from the basolateral side with various concentrations of CdCl2 for 24, 48, or 72 h. The cultures were washed briefly in PBS and TEER measurements (A) were conducted before processing the cultures for cytotoxicity evaluation using the MTS assay (B). Data (N = 3) are presented as means ± standard deviation. *p < 0.05 was considered to be significant compared to the vehicle-treated control.
Figure 3Induction of TJ disruption by CdCl . Cultures were treated from the basolateral side with 30, 50 and 100 μM CdCl2 for 24 h, and immunofluorescence staining was performed with antibodies for ZO-1 and occludin. Merged images demonstrated the colocalization of ZO-1 and occludin on the cellular borders in vehicle-treated control and 30 μM- and 50 μM-treated groups. Note apparent condensation of staining of ZO-1 and occludin in 100 μM CdCl2-treated cultures. Descriptions of the individual lettered panels are given in the text.
Figure 43D depiction of principal component analysis (PCA) of gene expression in cultures treated with vehicle, 30 μM CdCl , or 100 μM CdCl . Sixty five genes that met the criteria defined by the RT2 Profiler PCR Array Data Analysis v3.5 software from SABiosciences were uploaded to the ArrayTrack program. The PCA is based on the log2 ratios and expression profiles across all the 65 genes in the PCR array. The blue, green, and red dots indicate cultures treated with vehicle, 30 μM CdCl2, and 100 μM CdCl2, respectively. The first three principal components are plotted. The captured variance of PC1 (first principal component), PC2 (second principal component; the label is not shown), and PC3 (third principal component) were 45.79%, 31.70%, and 10.12%, respectively.
Significantly regulated TJ-related genes in response to CdCl treatment in human airway epithelial ALI cultures (fold change ≥ 1.5, value < 0.05)
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|
|
|
|
|
| |||
|
| ||||||
| ICAM1 | Intercellular adhesion molecule 1 | Cell surface receptors | 13.89 | 0.000114 | ||
| CRB3 | Crumbs homolog 3 (Drosophila) | Cell surface receptors | 3.95 | 0.000507 | ||
| CLDN1 | Claudin 1 | Cell surface receptors | 2.99 | 0.000232 | ||
| CLDN4 | Claudin 4 | Cell surface receptors | 2.57 | 0.012412 | ||
| OCLN | Occludin | Cell surface receptors | 2.53 | 0.000418 | ||
| ARHGEF2 | Rho/rac guanine nucleotide exchange factor 2 | G Protein signaling | 2.15 | 0.007405 | ||
| CLDN2 | Claudin 2 | Cell surface receptors | 2.14 | 0.045285 | ||
| TJP1 | Tight junction protein 1 (Zona occludens-1) | Junction interacting proteins | 2.13 | 0.00451 | ||
| SMURF1 | SMAD specific E3 ubiquitin protein ligase 1 | Cytoskeleton Regulator/G Protein Signaling | 1.71 | 0.005857 | ||
| CLDN12 | Claudin 12 | Cell surface receptors | 1.65 | 0.008749 | ||
| JAM3 | Junctional adhesion molecule 3 | Junction interacting proteins | 1.62 | 0.015438 | ||
| AMOTL1 | Angiomotin like 1 | Junction interacting proteins/Cytoskeleton regulation | 1.99 | 0.009748 | ||
| HCLS1 | Hematopoietic cell-specific Lyn substrate 1 | Junction interacting proteins | 1.62 | 0.017181 | ||
|
| ||||||
| MPDZ | Multiple PDZ domain protein | Junction interacting proteins | −7.35 | 0.000001 | ||
| PTEN | Phosphatase and tensin homolog | Protein kinase signaling | −4.22 | 0 | ||
| ICAM2 | Intercellular adhesion molecule 2 | Cell surface receptors | −4.01 | 0.019093 | ||
| CGN | Cingulin | Junction interacting proteins | −3.74 | 0.007739 | ||
| CDK4 | Cyclin-dependent kinase 4 | G Protein signaling | −3.58 | 0.012422 | ||
| CLDN16 | Claudin 16 | Cell surface receptors | −3.15 | 0.000298 | ||
| MAGI1 | Membrane associated guanylate kinase, WW and PDZ domain containing 1 | Junction interacting proteins/Protein kinase signaling | −3.13 | 0.000032 | ||
| CLDN8 | Claudin 8 | Cell surface receptors | −2.77 | 0.000306 | ||
| CLDN2 | Claudin 2 | Cell surface receptors | −1.96 | 0.03226 | ||
| GNAI1 | Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 | G Protein signaling | −2.70 | 0.000373 | ||
| VAPA | VAMP (vesicle-associated membrane protein)-associated protein A, 33kDa | Junction interacting proteins | −2.20 | 0.000723 | ||
| TJAP1 | Tight junction associated protein 1 (peripheral) | Junction interacting proteins | −2.20 | 0.028018 | ||
| ASH1L | Ash1 (absent, small, or homeotic)-like (Drosophila) | Cytoskeleton Regulator | −2.14 | 0.000877 | ||
| SYMPK | Symplekin | Junction interacting proteins | −2.07 | 0.040784 | ||
| CSNK2A2 | Casein kinase 2, alpha prime polypeptide | Protein kinase signaling | −1.97 | 0.004506 | ||
| CSDA | Cold shock domain protein A | Junction interacting proteins/Cytoskeleton regulator | −1.73 | 0.000039 | ||
| MPP6 | Membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) | Protein kinase signaling | −1.71 | 0.0007 | ||
| MLLT4 | Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 4 | Junction interacting proteins | −1.60 | 0.014185 | ||
| CSNK2A1 | Casein kinase 2, alpha 1 polypeptide | Protein kinase signaling | −1.55 | 0.002999 | ||
Figure 5Expression changes of TJ-related genes in cultures exposed basolaterally to 100 μM CdCl . The means of the gene expression changes are plotted. All genes presented here have a fold change ≥ 1.5 and p-value < 0.05. N = 4 for vehicle-treated control group; N = 3 for 100 μM CdCl2-treated group.
Figure 6Cingulin, TJAP1, and VAP-33 protein expression changes in response to CdCl treatment. Cultures were treated from the basolateral side with various concentrations of CdCl2 for 24 h, and whole cell lysate was collected and separated by electrophoresis. The expression of cingulin, TJAP1, and VAP-33 was detected by immunoblotting using specific antibodies. (A). Representative Western blots. (B). Density of the bands were quantified and statistically analyzed (N = 3). *Indicates p < 0.05 compared to the vehicle-treated control.
Figure 7Protective effects of kinase inhibitors for c-Src and PKC on Cd-induced TJ disruption. (A). TJ integrity was assessed using immunofluorescence staining of ZO-1 and occludin. Cotreatment of CdCl2 and kinase inhibitors prevented Cd-induced TJ disruption. Descriptions of the individual lettered panels are given in the text. (B). Representative Western blots showing protein expression of cingulin, TJAP1, and VAP-33. Kinase inhibitors failed to prevent the down-regulation of these junction-interacting proteins. (C). Density of the Western blots in Figure 7B. were quantified and statistically analyzed (N = 3). *Indicates p < 0.05 compared to the vehicle treated control. (D). Tyr-phosphorylation of occludin was modulated by CdCl2. Cultures were treated from the basolateral side with 100 μM CdCl2 in the presence or the absence of kinase inhibitors for c-Src or PKC. Tyrosine phosphorylated occludin was detected in occludin-enriched immunoprecipitates. Both kinase inhibitors prevented Tyr hyperphosphorylation of occludin.